Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

to monitor the efficacy of c-Met therapy in bladder cancer patients. Moreover, cabozantinib has demonstrated activity in heavily pretreated, advanced bladder cancer patients, with a response rate of

growth factor
metastatic cancer
gilbert's disease
transitional cell carcinoma
advanced urothelial carcinoma
  • 46 views
  • 22 Sep, 2021
  • 12 locations
To Evaluate the Safety Pharmacokinetics Pharmacodynamics and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors

This is a dose escalation, Phase 1-2 study of ABN401 in patients with advanced solid tumors, refractory metastatic disease, or refractory locally advanced disease not amenable to local therapy.

  • 3 views
  • 24 Jan, 2021
  • 8 locations
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with

measurable disease
cancer
c-MET
major surgery
lung cancer
  • 144 views
  • 02 Sep, 2021
  • 105 locations
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line

epidermal growth factor receptor
epidermal growth factor
growth factor
c-MET
EGFR
  • 119 views
  • 21 Sep, 2021
  • 381 locations
A Study Evaluating the Safety Pharmacokinetics (PK) and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

growth factor
bone marrow procedure
EGFR
treatment regimen
primary cancer
  • 49 views
  • 22 Sep, 2021
  • 52 locations
Visualising c-MET and Activated Neutrophils in Lung Cancer

boosts or inhibits cancer in the lungs remains unclear. This study aims to directly visualise the expression of a well known marker of cancerous tissue, c-MET, and the activity of neutrophils in human

cancer
absolute neutrophil count
ct scan
c-MET
lung cancer
  • 0 views
  • 06 May, 2021
  • 1 location
TR1801-ADC in Patients With Tumors That Express c-Met

First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of TR1801-ADC in patients with select solid tumors that express c-Met.

metastasis
solid tumour
  • 0 views
  • 15 Jul, 2021
  • 5 locations
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 15 patients Phase (globally): Approximately 90

  • 0 views
  • 18 Feb, 2021
  • 35 locations
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation

This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.

measurable disease
stage iv non-small cell lung cancer
c-MET
lung carcinoma
  • 1 views
  • 23 Jan, 2021
  • 1 location
Safety Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

The main objective of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC. Biomarkers related to the

measurable disease
c-MET
kidney function test
  • 18 views
  • 22 Sep, 2021
  • 2 locations